Replies to post #12809 on Todos Med Ltd (TOMDF)

[GreeseMonkey]

This statement is not correct.

We should own all of it because it is our IP and r&d

The IP and R&D was all done by Dr. Arad at NLC Pharma. Todos acquired NLC under terms of 52% Todos ownership and 48% NLC ownership with the agreement Todos would fund development and testing of NLC products Tollovir, Tollovid and Tollotest until the spinoff and capital raise, whereby NLC/3CL would fund the rest with the proceeds raised.

Todos has never owned 100% of the IP.

[DreyDreyDrey]

There is a lot in your post that doesn’t really make sense.

My understanding is this. And I have been wrong before. Basically, they start a new company, with a new management team. Their sole focus is Tollovir/vid. Todos will sell some of their 52% to investors. Give away some to new management team. And retain an unknown amount. If I had to guess I would say 25%. When (if) Tollovid/vir takes off. The hope is they will get bought out for a hundred million. Making it a great investment if it happens quickly. A decent investment if it takes awhile. And a crappy investment/bad decision if it goes under. Someone will then buy the IP for pennies on the dollar. But if it goes under. There probably wasn’t much there anyway. Unless it is miss managed. Which is a real possibility. I vote do it. Things are moving too slowly. Go big or go under.